Life Healthcare Group Holdings earnings date
Life Healthcare Group Holdings (LTGHF) Q4 2025 Earnings Report
LTGHF Q4 2025 EPS Results
- Actual EPS
- $0.24
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- $0.05
LTGHF Q4 2025 Revenue Results
- Actual Revenue
- $722.14M
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- -4.23%
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 11/27/2025
- Time
- Before Open
- Conference Call
- Thursday, November 27, 2025
Life Healthcare Group Holdings's next earnings date is estimated for November 26, 2026, based on past reporting schedules.
Q4 2025 Earnings Call Audio
Q4 2025 Earnings Slide Deck
Q4 2025 Earnings Call Summary
The call presented a broadly positive operational and financial picture: solid revenue growth, strong cash generation, improved occupancy (above 70% in H2), attractive returns to shareholders, and clear growth projects underway. However, material challenges remain — notably the underperformance and integration issues in the Fresenius renal business, a small number of underperforming hospitals requiring asset optimization, accounting complexity and a sizeable Piramal liability from the LMI disposal, and near-term impairment and cost pressure. Management has articulated concrete remediation plans (asset optimization, cost savings of ZAR 400m, operational fixes) and targets to restore margins.
Guidance for 2026 centres on growth, driving and optimisation with specific targets: management expects group occupancies of ~70%, PPD growth of ~1% and revenue growth of ~5%, plans to recruit ~140 specialists, deliver a 140‑bed greenfield (Life Paarl Valley) plus a further 89 acute beds (brownfield), add another cathlab and a vascular lab, deliver 40 acute rehabilitation beds, 20 renal stations and 3 PET‑CT sites, and bring cyclotrons into commercial production (Q2); it will acquire one remaining major property for ~ZAR 475m to own almost 100% of the portfolio, and pursue ZAR 400m of real cost savings over three years (20–25% of the saving targeted in year one), aim to restore Renal Dialysis margins to ~15–18% and complete all asset‑optimization decisions by year‑end 2026.
- Revenue GrowthGroup continuing operations revenue up 6% year-on-year; revenue per PPD grew 5.8% driven by a tariff increase of 5.1% and positive case mix.
- Normalized Earnings and ProfitabilityNormalized earnings per share from continuing operations ~10% (normalized EPS reported at 10.1% pro forma); normalized EBITDA on continuing operations +4.7%.
- Strong Cash Generation and Returns to ShareholdersOperating cash generation close to ZAR 4.6bn (up 23.8%); cash generation was 119.6% of EBITDA. Total shareholder distributions over the last 2 years ~ZAR 13bn; final dividend up 12% (ZAR 0.56) and total dividends for the year up ~12%.
- Occupancy and Activity RecoveryYear average occupancy 69.7% with second-half occupancy slightly over 70%; PPD (patient day) growth ~1.1% for the year and top-performing cohorts showing stronger activity (top 20: PPD growth 1.3%; top 30: PPD growth 1.5%).
- Strong Performance in Top HospitalsTop 20 hospitals: occupancy 72%, revenue growth 7.4% and EBITDA growth 10.3%. Top 30 hospitals: occupancy 71%, revenue growth 7.2% and EBITDA growth 9.6%; top 30 account for ~96% of acute EBITDA.
- Complementary Services ExpansionComplementary services revenue grew ~25% (including acquisitions); imaging and nuclear volumes increasing with 3 PET‑CTs expected in 2026 and cyclotrons awaiting regulatory sign-off; renal dialysis activity growth nearly 10% and Life Renal care moved to positive EBITDA in H2.
- Balance Sheet Strength and Credit RatingNet debt-to-EBITDA reported at 0.77 (including IFRS lease liabilities); credit rating improved to zaAAA. If Piramal liability treated as debt-like, net debt/EBITDA ~0.8 and management is comfortable with this leverage.
- Growth and Capacity AdditionsGreenfield 140-bed Life Paarl Valley project underway; brownfield additions: ~30 ICU/high-care beds and 39 general ward beds delivered during the year; plans to add a further 89 acute beds, 40 acute rehab beds, 20 renal stations and more imaging/cardiac labs in the coming year.
LTGHF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 26, 2026 | 2026 (Q4) | ―- | 0.24 | ― | ― |
| May 28, 2026 | 2026 (Q2) | ―0.03 | -0.09 | 137.65% (+0.12) | |
| Nov 27, 2025 | 2025 (Q4) | ―0.24 | 0.05 | 374.00% (+0.19) | |
| May 22, 2025 | 2025 (Q2) | ―-0.09 | 0.13 | -165.89% (-0.21) | |
| Nov 26, 2024 | 2024 (Q4) | ―0.05 | -0.01 | 600.00% (+0.06) | |
| May 22, 2024 | 2024 (Q2) | ―0.13 | 0.02 | 514.29% (+0.11) | |
| Nov 16, 2023 | 2023 (Q4) | ―-0.01 | 0.04 | -125.00% (-0.05) | |
| May 25, 2023 | 2023 (Q2) | ―0.02 | 0.03 | -22.22% (-0.01) | |
| Nov 17, 2022 | 2022 (Q4) | ―0.04 | 0.04 | -11.11% (-0.01) | |
| May 26, 2022 | 2022 (Q2) | ―0.03 | 0.03 | -20.59% (-0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

